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ABSTRACT. Sleep-related breathing disorders
are recognized as major health problems in obe-
sity. They are involved in both hypertension and
Type 2 diabetes, through mechanisms possibly
related to increased sympathetic tone. We stud-
ied the association of habitual snoring with dia-
betes, hypertension, weight cycling and physical
activity in a large Italian database of treatment-
seeking obese subjects. Clinical and behavioral
data were assessed by standardized question-
naires. Consecutive data of 1890 obese patients
were analyzed [average body mass index (BMI),
38.2 kg/m2, median age: 46 yr, 78% females], from
25 obesity Italian centers, with low prevalence of
clinical manifestations of cardiovascular disease.
Habitual snoring was reported in 56% of the cases,
and was associated with day-time sleepiness. The
prevalence increased with obesity class and waist
circumference, and was positively associated with
weight cycling and weight gain since the age of
20, and smoking. Regular physical activity had a
protective effect. Snoring was associated with di-
abetes and hypertension at univariate analysis, but
in multivariate analysis an independent effect was
only observed for hypertension. After adjustment
for age, gender and BMI, physical activity main-
tained an independent, protective effect on both
snoring (odds ratio 0.65, 95% confidence interval
0.49–0.84; p=0.001), diabetes (0.50, 0.30–0.86;
p=0.011) and hypertension (0.71, 0.53–0.95;
p=0.023). We conclude that in treatment-seeking,
obese subjects with low prevalence of cardiovas-
cular disease, snoring independently increases the
risk of hypertension, whereas physical activity ex-
erts a protection on both snoring and complica-
tions. These data underline the importance of
lifestyle interventions to limit the burden of obesity
and associated diseases.
(J. Endocrinol. Invest. 27: 150-157, 2004)
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INTRODUCTION
Obesity is a major threat to public health (1), and
complicating diseases contribute to morbidity and
mortality. Sleep-related breathing disorders (SRBD)
are recognized as major health problems in obesity
(2). SRBD range from habitual snoring – a disturbing
condition without clinical relevance in less severe cas-
es – to sleep apnea syndrome. The majority of pa-
tients have excessive daytime sleepiness and tired-
ness, which may be a problem at work (3) or driving
(4), but far more relevant problems may also ensue.
The coexistence of cardiovascular and cerebrovas-
cular diseases with sleep-related breathing disorders
was long considered the result of shared risk factors,
namely ageing, male gender, and obesity (5). In re-
cent years several epidemiologic studies have
demonstrated that SRBD are independent risk fac-
tors for hypertension (6-8), via increased sympa-
thoadrenal activity. A link between SRBD and Type
2 diabetes was also suggested (9). This association is
also biased by the common occurrence of obesity
and hypertension in both conditions, as well as by
weight cycling, whose role as a confounder on neg-
ative health outcomes, particularly cardiovascular
mortality, has never been definitely settled (10, 11).
However, it was suggested that sleep apnea might
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also impair insulin levels (12), insulin action and over-
all glucose regulation (9, 13), leading to diabetes
(14). An association was also reported between
weight cycling and major illnesses (15), contributing
to cardiovascular morbidity and mortality, and a pro-
tective role of physical activity was suggested (16).
The majority of studies based the association be-
tween SRBD and complications on well-established
demonstration of sleep-apnea syndrome, based on
whole night polysomnography (6-8, 13). The pre-
dictive value of self-reported habitual snoring is al-
so reported, but less clearly established (14, 17).
The QUOVADIS study (QUality of life in Obesity:
eVAluation and DIsease Surveillance) is an on-going
large, observational trial aimed at measuring the bur-
den of obesity and its complications on health-relat-
ed quality of life and psychological distress (18); sev-
eral clinical and laboratory data were collected in
consecutive patients attending 25 obesity centers.
The present study specifically aimed at: 1) measur-
ing the prevalence of self-reported habitual snor-
ing in obese patients; 2) assessing the association of
hypertension and Type 2 diabetes with clinical da-
ta, and specifically with snoring, weight gain and
weight cycling.
MATERIALS AND METHODS
Patients
We report data on 1890 obese patients (Table 1), enrolled by
25 Italian centers in the observational QUOVADIS study, pro-
viding a complete picture of obese patients seeking treatment
at Italian obesity centers. The protocol of the study and the main
features of patients have been previously reported (18). All treat-
ment-seeking obese subjects were eligible for the study, pro-
vided they were not on active treatment for obesity at the time
of enrolment, were in the age range between 20 and 65 yr,
agreed to fill a package of self-administered questionnaires, and
signed an informed consent to participate. 
Recorded clinical data also included cigarette smoking, an eval-
uation of self-reported structured physical activity, a previous
diagnosis of hypertension (or treatment with arterial pressure
lowering drugs) and clinically detected coronary heart and pe-
ripheral vascular disease. Patients were not systematically
screened for coronary heart disease (CHD) by electrocardiogram
or Doppler ultrasounds.
Snoring was specifically investigated by systematically asking
patients about previous reports by relatives of their sleeping pat-
tern, occasional or habitual snoring, and age since first report, us-
ing standardized questions. Although a few patients reported
symptoms suggestive of obstructive sleep apnea syndrome, this
diagnosis was not systematically investigated. Referred data on
habitual snoring were compared with the response to a specif-
ic item of the obesity-related well-being (ORWELL-97) self-ad-
ministered questionnaire (19), enquiring about daytime sleepi-
ness and its influence on daily activities. The questions “Do you
ever feel sleepy?” and “Does sleepiness interfere with your dai-
ly activities?” were considered. However, in statistical analysis,
snoring was considered on the sole basis of self-reported as-
sessment, independently of daytime sleepiness.
Finally, the weight history was checked by the assessment of body
weight at the age of 20 yr and the number of times patients had lost
weight as an effect of dietary programs. For this purpose, a grid
was included in the Case Report Form and patients were system-
atically interviewed as to the number of times they had lost more
than 30 kg, 20 to 30 kg, 10 to 20 kg, 5 to 10 kg or less than 5 kg be-
cause of programmed dietary restriction. The values were used to
compute the total number of dieting programs and total cumula-
tive weight loss. The sum of total weight loss and the difference
Table 1 - Characteristics of the 1890 patients under study
(prevalent and 95% confidence interval or median and range).
Male gender (%) 22.1 (20.2 – 24.0)
Age (yr) (median and range) 46 (20 – 65)
Waist circumference 94.6 (93.4 – 95.5)
>102 cm (M) or >88 cm (F)
Body Mass Index (kg/m2) 38.2 (30.0 – 82.2)
(median and range)
Obesity class I (30 to 34.9 kg/m2) (%) 38.4 (36.2 – 40.5)
Obesity class II (35 to 39.9 kg/m2) (%) 28.3 (26.3 – 30.3)
Obesity class III (>40 kg/m2) (%) 33.4 (31.2 – 35.5)
Weight (kg) (median and range) 98 (66 – 200)
Weight at the age of 20 yr (kg) 65 (39 – 150)
(median and range)
Previous attempts to lose weight (%) 81.7 (79.9 – 83.4)
No. of attempts (median and range) 3 (0 – over 20)
Age at first attempt (median and range) 26 (<10 – 63)
Structured physical activity (%) 15.8 (14.2 – 17.5)
H of physical activity/week (median and range)2 (1 – over 15)
Active smokers (%) 22.6 (20.8 – 24.5)
Previous smokers (%) 22.4 (20.5 – 24.3)
Snoring (%) 56.1 (53.8 – 58.3)
Snoring by over 5 yr (%) 33.6 (31.5 – 35.7)
Daytime sleepiness (%) 42.6 (40.4 – 44.8)
Family history of coronary disease (%)° 2.6 (1.9 – 3.4)
Family history of diabetes (%)# 43.6 (41.4 – 45.9)
Total with diabetes (%) 12.8 (11.3 – 14.4)
Previously diagnosed diabetes (%) 9.3 (8.0 – 10.6)
Newly detected diabetes 2.7 (2.1 – 3.6)
(BG Γ126 mg/dl) (%)
Newly detected diabetes 2.0 (1.2 – 3.2)
(120-min BG Γ200 mg/dl) (no.=834) (%)
Total with hypertension (%) 62.3 (60.1 – 64.5)
Previously diagnosed hypertension (%) 36.5 (34.3 – 38.6)
Newly detected hypertension 26.7 (24.7 – 28.7)
(Γ140/90 mmHg) (%)
Total with hyperlipidemia (%) 65.9 (63.7 – 68.0)
Previously diagnosed hyperlipidemia (%) 22.7 (20.8 – 24.6)
Newly detected hyperlipidemia (%)* 44.4 (42.1 – 46.7)
Coronary heart disease (%) 2.6 (1.9 – 3.4)
Peripheral vascular disease (%) 0.8 (0.5 – 1.3)
*: LDL-cholesterol Γ130 mg/dl and/or triglycerides Γ150 mg/dl, or
statins/fibrates use; °: First degree relatives (males, age <55 yr; females,
<65 yr); #: First and second degree relatives.
